SCHEMBL24166643

SCHEMBL24166643

C=C/C=C\C=C(C)\C=C(/NC(=O)/C=C/c1ccccc1)C(=O)Nc1cccnc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.55
NPC1 O15118 8/20 0.55
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
ALDH1A1 P00352 8/20 0.46
NPSR1 Q6W5P4 1/20 0.46
PKM P14618 3/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
MAPT P10636 3/20 0.42
POLB P06746 1/20 0.42
MAPK1 P28482 1/20 0.41
KDM4E B2RXH2 4/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
BLM P54132 1/20 0.41
NAMPT P43490 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HDAC4 P56524 1/20 0.41
MEF2D Q14814 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22645461 0.80 NPC1 (0.70) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL16180694 0.73 RAB9A (1.00) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL21593633 0.73 RAB9A (1.00) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL22692996 0.70 MAPT (0.62) MEN1KMT2AALDH1A1NPSR1SMN1; SMN2
SCHEMBL4987866 0.66 NPC1 (0.73) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL22926452 0.65 RAB9A (0.47) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL18407399 0.65 RAB9A (0.76) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL24723929 0.65 HDAC3 (0.51) RAB9ANPC1KMT2AALDH1A1SMN1; SMN2
SCHEMBL22645323 0.65 HDAC3 (0.53) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL22662529 0.65 HDAC3 (0.53) RAB9ANPC1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11214556-B1 Method of treating colorectal cancer KING ABDULAZIZ UNIVERSITY (SA) 2022-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11214556-B1 Method of treating colorectal cancer APC, SLC10A2, FOLR1 RAB9A 2623/4885NPC1 343/4885MEN1 1111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.